Congenital adrenal hyperplasia
Conditions
Interventions
n.v.t.
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Age
16 Years to 99 Years
Inclusion criteria
Inclusion criteria: For all groups: • Aged >= 16 years • Capable of providing informed consent Inclusion criteria for patients with CAH: • Diagnosed with classical CAH Inclusion criteria for patients with Cushing*s syndrome • Diagnosed with Cushing*s syndrome • Not currently receiving any form of treatment for Cushing's syndrome (e.g., no surgical interventions aimed at reducing cortisol production)
Exclusion criteria
Exclusion criteria: • Unable to provide informed consent • Pregnancy • Use of systemic glucocorticoids for medical indications other than the treatment of CAH within the past 3 months. • Active inflammatory or infectious comorbidities • Acute illness or infection in the past 2 weeks
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameters are the inhibition of lipopolysaccharide (LPS)-induced cytokine production in peripheral blood mononuclear cells (PBMCs) after ex vivo glucocorticoid exposure (measure of GRS) and the expression of genes indicative of GRA, such as FKBP5. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes will comprise serum/saliva cortisol, PS, and AA levels and clinical outcomes. | — |
Countries
Netherlands
Contacts
Public ContactE.E.W. Verploegen
Radboud Universitair Medisch Centrum
Outcome results
None listed